GXIPC1

Patients with diabetes either have pancreatic cells that cannot produce enough insulin (insulin deficiency) or have impaired insulin function (insulin resistance). This prevents glucose from entering the cells, causing blood glucose concentrations to rise, which ultimately leads to diabetes. Current mainstream treatments for diabetes can, at best, only control the symptoms and require lifelong medication or insulin use, as they cannot cure the disease.

Furthermore, while there have been successful cases of pancreas transplants in Taiwan, the transplant process is cumbersome. In addition to the long wait and matching procedures, there's no guarantee of a successful transplant. This makes the development of a convenient treatment that does not require waiting or matching and can be directly applied of great importance.

GWOXI's new stem cell drug, "GXIPC1 E-Glucos," has been experimentally proven to effectively improve diabetic conditions by controlling blood glucose, maintaining the number of pancreatic islets, and keeping the islet morphology full. This research achievement has also been granted an invention patent.

In 2019, GWOXI partnered with a medical institution under the Vinmec Group in Vietnam to jointly develop a stem cell new drug for diabetes. In July 2021, the company obtained approval from the Vietnamese Ministry of Health (MOH) to proceed with a Phase I clinical trial. In the future, it is hoped that GXIPC1 can offer a new treatment option for diabetic patients and contribute to their well-being.